APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bevacizumab

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Bevacizumab Market Analysis and Forecast 2026-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchBevacizumab Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Bevacizumab Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Bevacizumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bevacizumab Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Bevacizumab Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Bevacizumab market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Bevacizumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Bevacizumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Bevacizumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Bevacizumab is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Bevacizumab include Mylan, Genentech, Amgen, MVASI (bevacizumab), Beacon Pharmaceuticals Limited, Balaji Medical Services Private Limited and Aark Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Bevacizumab, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Bevacizumab, also provides the sales of main regions and countries. Of the upcoming market potential for Bevacizumab, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Bevacizumab sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Bevacizumab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Bevacizumab sales, projected growth trends, production technology, application and end-user industry.

Bevacizumab Segment by Company

Mylan

Genentech

Amgen

MVASI (bevacizumab)

Beacon Pharmaceuticals Limited

Balaji Medical Services Private Limited

Aark Pharmaceuticals

Bevacizumab Segment by Type

Avastin (bevacizumab)

Mvasi (bevacizumab-awwb)

Bevacizumab Segment by Application

Cancer

Eye Diease

Bevacizumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Bevacizumab in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Bevacizumab manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bevacizumab sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Bevacizumab Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Avastin (bevacizumab) Major Manufacturers Table 3. Mvasi (bevacizumab-awwb) Major Manufacturers Table 4. Global Bevacizumab Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cancer Major Manufacturers Table 6. Eye Diease Major Manufacturers Table 7. Bevacizumab Industry Trends Table 8. Bevacizumab Industry Drivers Table 9. Bevacizumab Industry Opportunities and Challenges Table 10. Bevacizumab Industry Restraints Table 11. Global Bevacizumab Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Bevacizumab Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Bevacizumab Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Bevacizumab Revenue Market Share by Region (2021-2026) Table 15. Global Bevacizumab Revenue Market Share by Region (2027-2032) Table 16. Global Bevacizumab Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 17. Global Bevacizumab Sales by Region (2021-2026) & (k units) Table 18. Global Bevacizumab Sales by Region (2027-2032) & (k units) Table 19. Global Bevacizumab Sales Market Share by Region (2021-2026) Table 20. Global Bevacizumab Sales Market Share by Region (2027-2032) Table 21. Global Bevacizumab Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Bevacizumab Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Bevacizumab Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Bevacizumab Sales Market Share by Manufacturers (2021-2026) Table 25. Global Bevacizumab Sales Price (US$/unit) of Manufacturers (2021-2026) Table 26. Global Bevacizumab Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Bevacizumab Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Bevacizumab Manufacturers, Product Type & Application Table 29. Global Bevacizumab Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Bevacizumab by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Bevacizumab Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Bevacizumab Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Bevacizumab Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Bevacizumab Revenue Market Share by Type (2021-2026) Table 36. Global Bevacizumab Revenue Market Share by Type (2027-2032) Table 37. Global Bevacizumab Sales by Type 2021 VS 2025 VS 2032 (k units) Table 38. Global Bevacizumab Sales by Type (2021-2026) & (k units) Table 39. Global Bevacizumab Sales by Type (2027-2032) & (k units) Table 40. Global Bevacizumab Sales Market Share by Type (2021-2026) Table 41. Global Bevacizumab Sales Market Share by Type (2027-2032) Table 42. Global Bevacizumab Price by Type (2021-2026) & (US$/unit) Table 43. Global Bevacizumab Price by Type (2027-2032) & (US$/unit) Table 44. Global Bevacizumab Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Bevacizumab Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Bevacizumab Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Bevacizumab Revenue Market Share by Application (2021-2026) Table 48. Global Bevacizumab Revenue Market Share by Application (2027-2032) Table 49. Global Bevacizumab Sales by Application 2021 VS 2025 VS 2032 (k units) Table 50. Global Bevacizumab Sales by Application (2021-2026) & (k units) Table 51. Global Bevacizumab Sales by Application (2027-2032) & (k units) Table 52. Global Bevacizumab Sales Market Share by Application (2021-2026) Table 53. Global Bevacizumab Sales Market Share by Application (2027-2032) Table 54. Global Bevacizumab Price by Application (2021-2026) & (US$/unit) Table 55. Global Bevacizumab Price by Application (2027-2032) & (US$/unit) Table 56. Mylan Company Information Table 57. Mylan Business Overview Table 58. Mylan Bevacizumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 59. Mylan Bevacizumab Product Portfolio Table 60. Mylan Recent Development Table 61. Genentech Company Information Table 62. Genentech Business Overview Table 63. Genentech Bevacizumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 64. Genentech Bevacizumab Product Portfolio Table 65. Genentech Recent Development Table 66. Amgen Company Information Table 67. Amgen Business Overview Table 68. Amgen Bevacizumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Amgen Bevacizumab Product Portfolio Table 70. Amgen Recent Development Table 71. MVASI (bevacizumab) Company Information Table 72. MVASI (bevacizumab) Business Overview Table 73. MVASI (bevacizumab) Bevacizumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. MVASI (bevacizumab) Bevacizumab Product Portfolio Table 75. MVASI (bevacizumab) Recent Development Table 76. Beacon Pharmaceuticals Limited Company Information Table 77. Beacon Pharmaceuticals Limited Business Overview Table 78. Beacon Pharmaceuticals Limited Bevacizumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Beacon Pharmaceuticals Limited Bevacizumab Product Portfolio Table 80. Beacon Pharmaceuticals Limited Recent Development Table 81. Balaji Medical Services Private Limited Company Information Table 82. Balaji Medical Services Private Limited Business Overview Table 83. Balaji Medical Services Private Limited Bevacizumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Balaji Medical Services Private Limited Bevacizumab Product Portfolio Table 85. Balaji Medical Services Private Limited Recent Development Table 86. Aark Pharmaceuticals Company Information Table 87. Aark Pharmaceuticals Business Overview Table 88. Aark Pharmaceuticals Bevacizumab Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Aark Pharmaceuticals Bevacizumab Product Portfolio Table 90. Aark Pharmaceuticals Recent Development Table 91. North America Bevacizumab Revenue by Type (2021-2026) & (US$ Million) Table 92. North America Bevacizumab Revenue by Type (2027-2032) & (US$ Million) Table 93. North America Bevacizumab Sales by Type (2021-2026) & (k units) Table 94. North America Bevacizumab Sales by Type (2027-2032) & (k units) Table 95. North America Bevacizumab Sales Price by Type (2021-2026) & (US$/unit) Table 96. North America Bevacizumab Sales Price by Type (2027-2032) & (US$/unit) Table 97. North America Bevacizumab Revenue by Application (2021-2026) & (US$ Million) Table 98. North America Bevacizumab Revenue by Application (2027-2032) & (US$ Million) Table 99. North America Bevacizumab Sales by Application (2021-2026) & (k units) Table 100. North America Bevacizumab Sales by Application (2027-2032) & (k units) Table 101. North America Bevacizumab Sales Price by Application (2021-2026) & (US$/unit) Table 102. North America Bevacizumab Sales Price by Application (2027-2032) & (US$/unit) Table 103. North America Bevacizumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. North America Bevacizumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 105. North America Bevacizumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 106. North America Bevacizumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 107. North America Bevacizumab Sales by Country (2021-2026) & (k units) Table 108. North America Bevacizumab Sales by Country (2027-2032) & (k units) Table 109. North America Bevacizumab Sales Price by Country (2021-2026) & (US$/unit) Table 110. North America Bevacizumab Sales Price by Country (2027-2032) & (US$/unit) Table 111. United States Bevacizumab Revenue (2021-2032) & (US$ Million) Table 112. Canada Bevacizumab Revenue (2021-2032) & (US$ Million) Table 113. Mexico Bevacizumab Revenue (2021-2032) & (US$ Million) Table 114. Europe Bevacizumab Revenue by Type (2021-2026) & (US$ Million) Table 115. Europe Bevacizumab Revenue by Type (2027-2032) & (US$ Million) Table 116. Europe Bevacizumab Sales by Type (2021-2026) & (k units) Table 117. Europe Bevacizumab Sales by Type (2027-2032) & (k units) Table 118. Europe Bevacizumab Sales Price by Type (2021-2026) & (US$/unit) Table 119. Europe Bevacizumab Sales Price by Type (2027-2032) & (US$/unit) Table 120. Europe Bevacizumab Revenue by Application (2021-2026) & (US$ Million) Table 121. Europe Bevacizumab Revenue by Application (2027-2032) & (US$ Million) Table 122. Europe Bevacizumab Sales by Application (2021-2026) & (k units) Table 123. Europe Bevacizumab Sales by Application (2027-2032) & (k units) Table 124. Europe Bevacizumab Sales Price by Application (2021-2026) & (US$/unit) Table 125. Europe Bevacizumab Sales Price by Application (2027-2032) & (US$/unit) Table 126. Europe Bevacizumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Europe Bevacizumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 128. Europe Bevacizumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 129. Europe Bevacizumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 130. Europe Bevacizumab Sales by Country (2021-2026) & (k units) Table 131. Europe Bevacizumab Sales by Country (2027-2032) & (k units) Table 132. Europe Bevacizumab Sales Price by Country (2021-2026) & (US$/unit) Table 133. Europe Bevacizumab Sales Price by Country (2027-2032) & (US$/unit) Table 134. Germany Bevacizumab Revenue (2021-2032) & (US$ Million) Table 135. France Bevacizumab Revenue (2021-2032) & (US$ Million) Table 136. U.K. Bevacizumab Revenue (2021-2032) & (US$ Million) Table 137. Italy Bevacizumab Revenue (2021-2032) & (US$ Million) Table 138. Russia Bevacizumab Revenue (2021-2032) & (US$ Million) Table 139. Spain Bevacizumab Revenue (2021-2032) & (US$ Million) Table 140. Netherlands Bevacizumab Revenue (2021-2032) & (US$ Million) Table 141. Switzerland Bevacizumab Revenue (2021-2032) & (US$ Million) Table 142. Sweden Bevacizumab Revenue (2021-2032) & (US$ Million) Table 143. Poland Bevacizumab Revenue (2021-2032) & (US$ Million) Table 144. China Bevacizumab Revenue by Type (2021-2026) & (US$ Million) Table 145. China Bevacizumab Revenue by Type (2027-2032) & (US$ Million) Table 146. China Bevacizumab Sales by Type (2021-2026) & (k units) Table 147. China Bevacizumab Sales by Type (2027-2032) & (k units) Table 148. China Bevacizumab Sales Price by Type (2021-2026) & (US$/unit) Table 149. China Bevacizumab Sales Price by Type (2027-2032) & (US$/unit) Table 150. China Bevacizumab Revenue by Application (2021-2026) & (US$ Million) Table 151. China Bevacizumab Revenue by Application (2027-2032) & (US$ Million) Table 152. China Bevacizumab Sales by Application (2021-2026) & (k units) Table 153. China Bevacizumab Sales by Application (2027-2032) & (k units) Table 154. China Bevacizumab Sales Price by Application (2021-2026) & (US$/unit) Table 155. China Bevacizumab Sales Price by Application (2027-2032) & (US$/unit) Table 156. Asia Bevacizumab Revenue by Type (2021-2026) & (US$ Million) Table 157. Asia Bevacizumab Revenue by Type (2027-2032) & (US$ Million) Table 158. Asia Bevacizumab Sales by Type (2021-2026) & (k units) Table 159. Asia Bevacizumab Sales by Type (2027-2032) & (k units) Table 160. Asia Bevacizumab Sales Price by Type (2021-2026) & (US$/unit) Table 161. Asia Bevacizumab Sales Price by Type (2027-2032) & (US$/unit) Table 162. Asia Bevacizumab Revenue by Application (2021-2026) & (US$ Million) Table 163. Asia Bevacizumab Revenue by Application (2027-2032) & (US$ Million) Table 164. Asia Bevacizumab Sales by Application (2021-2026) & (k units) Table 165. Asia Bevacizumab Sales by Application (2027-2032) & (k units) Table 166. Asia Bevacizumab Sales Price by Application (2021-2026) & (US$/unit) Table 167. Asia Bevacizumab Sales Price by Application (2027-2032) & (US$/unit) Table 168. Asia Bevacizumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. Asia Bevacizumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 170. Asia Bevacizumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 171. Asia Bevacizumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 172. Asia Bevacizumab Sales by Country (2021-2026) & (k units) Table 173. Asia Bevacizumab Sales by Country (2027-2032) & (k units) Table 174. Asia Bevacizumab Sales Price by Country (2021-2026) & (US$/unit) Table 175. Asia Bevacizumab Sales Price by Country (2027-2032) & (US$/unit) Table 176. Japan Bevacizumab Revenue (2021-2032) & (US$ Million) Table 177. South Korea Bevacizumab Revenue (2021-2032) & (US$ Million) Table 178. India Bevacizumab Revenue (2021-2032) & (US$ Million) Table 179. Australia Bevacizumab Revenue (2021-2032) & (US$ Million) Table 180. Taiwan Bevacizumab Revenue (2021-2032) & (US$ Million) Table 181. Southeast Asia Bevacizumab Revenue (2021-2032) & (US$ Million) Table 182. SAMEA Bevacizumab Revenue by Type (2021-2026) & (US$ Million) Table 183. SAMEA Bevacizumab Revenue by Type (2027-2032) & (US$ Million) Table 184. SAMEA Bevacizumab Sales by Type (2021-2026) & (k units) Table 185. SAMEA Bevacizumab Sales by Type (2027-2032) & (k units) Table 186. SAMEA Bevacizumab Sales Price by Type (2021-2026) & (US$/unit) Table 187. SAMEA Bevacizumab Sales Price by Type (2027-2032) & (US$/unit) Table 188. SAMEA Bevacizumab Revenue by Application (2021-2026) & (US$ Million) Table 189. SAMEA Bevacizumab Revenue by Application (2027-2032) & (US$ Million) Table 190. SAMEA Bevacizumab Sales by Application (2021-2026) & (k units) Table 191. SAMEA Bevacizumab Sales by Application (2027-2032) & (k units) Table 192. SAMEA Bevacizumab Sales Price by Application (2021-2026) & (US$/unit) Table 193. SAMEA Bevacizumab Sales Price by Application (2027-2032) & (US$/unit) Table 194. SAMEA Bevacizumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 195. SAMEA Bevacizumab Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 196. SAMEA Bevacizumab Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 197. SAMEA Bevacizumab Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 198. SAMEA Bevacizumab Sales by Country (2021-2026) & (k units) Table 199. SAMEA Bevacizumab Sales by Country (2027-2032) & (k units) Table 200. SAMEA Bevacizumab Sales Price by Country (2021-2026) & (US$/unit) Table 201. SAMEA Bevacizumab Sales Price by Country (2027-2032) & (US$/unit) Table 202. Brazil Bevacizumab Revenue (2021-2032) & (US$ Million) Table 203. Argentina Bevacizumab Revenue (2021-2032) & (US$ Million) Table 204. Chile Bevacizumab Revenue (2021-2032) & (US$ Million) Table 205. Colombia Bevacizumab Revenue (2021-2032) & (US$ Million) Table 206. Peru Bevacizumab Revenue (2021-2032) & (US$ Million) Table 207. Saudi Arabia Bevacizumab Revenue (2021-2032) & (US$ Million) Table 208. Israel Bevacizumab Revenue (2021-2032) & (US$ Million) Table 209. UAE Bevacizumab Revenue (2021-2032) & (US$ Million) Table 210. Turkey Bevacizumab Revenue (2021-2032) & (US$ Million) Table 211. Iran Bevacizumab Revenue (2021-2032) & (US$ Million) Table 212. Egypt Bevacizumab Revenue (2021-2032) & (US$ Million) Table 213. Key Raw Materials Table 214. Raw Materials Key Suppliers Table 215. Bevacizumab Distributors List Table 216. Bevacizumab Customers List Table 217. Research Programs/Design for This Report Table 218. Authors List of This Report Table 219. Secondary Sources Table 220. Primary Sources List of Figures Figure 1. Bevacizumab Image Figure 2. Global Bevacizumab Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bevacizumab Market Size Share 2021 VS 2025 VS 2032 Figure 4. Avastin (bevacizumab) Image Figure 5. Mvasi (bevacizumab-awwb) Image Figure 6. Global Bevacizumab Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Bevacizumab Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cancer Image Figure 9. Eye Diease Image Figure 10. Global Bevacizumab Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Bevacizumab Revenue (2021-2032) & (US$ Million) Figure 12. Global Bevacizumab Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Bevacizumab Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Bevacizumab Revenue Market Share by Region (2021-2032) Figure 15. Global Bevacizumab Sales (2021-2032) & (k units) Figure 16. Global Bevacizumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 17. Global Bevacizumab Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Bevacizumab Sales YoY (2021-2032) & (k units) Figure 19. Europe Bevacizumab Sales YoY (2021-2032) & (k units) Figure 20. China Bevacizumab Sales YoY (2021-2032) & (k units) Figure 21. Asia (Excluding China) Bevacizumab Sales YoY (2021-2032) & (k units) Figure 22. South America, Middle East and Africa Bevacizumab Sales YoY (2021-2032) & (k units) Figure 23. Global Bevacizumab Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Bevacizumab Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Bevacizumab Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Bevacizumab Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Bevacizumab Revenue Market Share by Type (2021-2032) Figure 29. Global Bevacizumab Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 30. Global Bevacizumab Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Bevacizumab Sales Market Share by Type (2021-2032) Figure 32. Global Bevacizumab Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Bevacizumab Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Bevacizumab Revenue Market Share by Application (2021-2032) Figure 35. Global Bevacizumab Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 36. Global Bevacizumab Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Bevacizumab Sales Market Share by Application (2021-2032) Figure 38. North America Bevacizumab Revenue Share by Type (2021-2032) Figure 39. North America Bevacizumab Sales Share by Type (2021-2032) Figure 40. North America Bevacizumab Revenue Share by Application (2021-2032) Figure 41. North America Bevacizumab Sales Share by Application (2021-2032) Figure 42. North America Bevacizumab Revenue Share by Country (2021-2032) Figure 43. North America Bevacizumab Sales Share by Country (2021-2032) Figure 44. Europe Bevacizumab Revenue Share by Type (2021-2032) Figure 45. Europe Bevacizumab Sales Share by Type (2021-2032) Figure 46. Europe Bevacizumab Revenue Share by Application (2021-2032) Figure 47. Europe Bevacizumab Sales Share by Application (2021-2032) Figure 48. Europe Bevacizumab Revenue Share by Country (2021-2032) Figure 49. Europe Bevacizumab Sales Share by Country (2021-2032) Figure 50. China Bevacizumab Revenue Share by Type (2021-2032) Figure 51. China Bevacizumab Sales Share by Type (2021-2032) Figure 52. China Bevacizumab Revenue Share by Application (2021-2032) Figure 53. China Bevacizumab Sales Share by Application (2021-2032) Figure 54. Asia Bevacizumab Revenue Share by Type (2021-2032) Figure 55. Asia Bevacizumab Sales Share by Type (2021-2032) Figure 56. Asia Bevacizumab Revenue Share by Application (2021-2032) Figure 57. Asia Bevacizumab Sales Share by Application (2021-2032) Figure 58. Asia Bevacizumab Revenue Share by Country (2021-2032) Figure 59. Asia Bevacizumab Sales Share by Country (2021-2032) Figure 60. SAMEA Bevacizumab Revenue Share by Type (2021-2032) Figure 61. SAMEA Bevacizumab Sales Share by Type (2021-2032) Figure 62. SAMEA Bevacizumab Revenue Share by Application (2021-2032) Figure 63. SAMEA Bevacizumab Sales Share by Application (2021-2032) Figure 64. SAMEA Bevacizumab Revenue Share by Country (2021-2032) Figure 65. SAMEA Bevacizumab Sales Share by Country (2021-2032) Figure 66. Bevacizumab Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Bevacizumab Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Avastin (bevacizumab)
  • Mvasi (bevacizumab-awwb)
Applications
  • Cancer
  • Eye Diease
Companies covered
  • Mylan
  • Genentech
  • Amgen
  • MVASI (bevacizumab)
  • Beacon Pharmaceuticals Limited
  • Balaji Medical Services Private Limited
  • Aark Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Bevacizumab Market by Type
  3. 1.2.1 Global Bevacizumab Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Avastin (bevacizumab)
  5. 1.2.3 Mvasi (bevacizumab-awwb)
  6. 1.3 Bevacizumab Market by Application
  7. 1.3.1 Global Bevacizumab Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Eye Diease
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Bevacizumab Market Dynamics
  1. 2.1 Bevacizumab Industry Trends
  2. 2.2 Bevacizumab Industry Drivers
  3. 2.3 Bevacizumab Industry Opportunities and Challenges
  4. 2.4 Bevacizumab Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Bevacizumab Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Bevacizumab Revenue by Region
  3. 3.2.1 Global Bevacizumab Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Bevacizumab Revenue by Region (2021-2026)
  5. 3.2.3 Global Bevacizumab Revenue by Region (2027-2032)
  6. 3.2.4 Global Bevacizumab Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Bevacizumab Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Bevacizumab Sales by Region
  9. 3.4.1 Global Bevacizumab Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Bevacizumab Sales by Region (2021-2026)
  11. 3.4.3 Global Bevacizumab Sales by Region (2027-2032)
  12. 3.4.4 Global Bevacizumab Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Bevacizumab Revenue by Manufacturers
  2. 4.1.1 Global Bevacizumab Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Bevacizumab Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Bevacizumab Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Bevacizumab Sales by Manufacturers
  6. 4.2.1 Global Bevacizumab Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Bevacizumab Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Bevacizumab Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Bevacizumab Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Bevacizumab Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Bevacizumab Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Bevacizumab Manufacturers, Product Type & Application
  13. 4.7 Global Bevacizumab Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Bevacizumab Market CR5 and HHI
  16. 4.8.2 2025 Bevacizumab Tier 1, Tier 2, and Tier 3
5 Bevacizumab Market by Type
  1. 5.1 Global Bevacizumab Revenue by Type
  2. 5.1.1 Global Bevacizumab Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Bevacizumab Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Bevacizumab Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Bevacizumab Sales by Type
  6. 5.2.1 Global Bevacizumab Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Bevacizumab Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Bevacizumab Sales Market Share by Type (2021-2032)
  9. 5.3 Global Bevacizumab Price by Type
6 Bevacizumab Market by Application
  1. 6.1 Global Bevacizumab Revenue by Application
  2. 6.1.1 Global Bevacizumab Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Bevacizumab Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Bevacizumab Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Bevacizumab Sales by Application
  6. 6.2.1 Global Bevacizumab Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Bevacizumab Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Bevacizumab Sales Market Share by Application (2021-2032)
  9. 6.3 Global Bevacizumab Price by Application
7 Company Profiles
  1. 7.1 Mylan
  2. 7.1.1 Mylan Company Information
  3. 7.1.2 Mylan Business Overview
  4. 7.1.3 Mylan Bevacizumab Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Mylan Bevacizumab Product Portfolio
  6. 7.1.5 Mylan Recent Developments
  7. 7.2 Genentech
  8. 7.2.1 Genentech Company Information
  9. 7.2.2 Genentech Business Overview
  10. 7.2.3 Genentech Bevacizumab Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Genentech Bevacizumab Product Portfolio
  12. 7.2.5 Genentech Recent Developments
  13. 7.3 Amgen
  14. 7.3.1 Amgen Company Information
  15. 7.3.2 Amgen Business Overview
  16. 7.3.3 Amgen Bevacizumab Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Amgen Bevacizumab Product Portfolio
  18. 7.3.5 Amgen Recent Developments
  19. 7.4 MVASI (bevacizumab)
  20. 7.4.1 MVASI (bevacizumab) Company Information
  21. 7.4.2 MVASI (bevacizumab) Business Overview
  22. 7.4.3 MVASI (bevacizumab) Bevacizumab Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 MVASI (bevacizumab) Bevacizumab Product Portfolio
  24. 7.4.5 MVASI (bevacizumab) Recent Developments
  25. 7.5 Beacon Pharmaceuticals Limited
  26. 7.5.1 Beacon Pharmaceuticals Limited Company Information
  27. 7.5.2 Beacon Pharmaceuticals Limited Business Overview
  28. 7.5.3 Beacon Pharmaceuticals Limited Bevacizumab Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Beacon Pharmaceuticals Limited Bevacizumab Product Portfolio
  30. 7.5.5 Beacon Pharmaceuticals Limited Recent Developments
  31. 7.6 Balaji Medical Services Private Limited
  32. 7.6.1 Balaji Medical Services Private Limited Company Information
  33. 7.6.2 Balaji Medical Services Private Limited Business Overview
  34. 7.6.3 Balaji Medical Services Private Limited Bevacizumab Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Balaji Medical Services Private Limited Bevacizumab Product Portfolio
  36. 7.6.5 Balaji Medical Services Private Limited Recent Developments
  37. 7.7 Aark Pharmaceuticals
  38. 7.7.1 Aark Pharmaceuticals Company Information
  39. 7.7.2 Aark Pharmaceuticals Business Overview
  40. 7.7.3 Aark Pharmaceuticals Bevacizumab Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Aark Pharmaceuticals Bevacizumab Product Portfolio
  42. 7.7.5 Aark Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Bevacizumab Market Size by Type
  2. 8.1.1 North America Bevacizumab Revenue by Type (2021-2032)
  3. 8.1.2 North America Bevacizumab Sales by Type (2021-2032)
  4. 8.1.3 North America Bevacizumab Price by Type (2021-2032)
  5. 8.2 North America Bevacizumab Market Size by Application
  6. 8.2.1 North America Bevacizumab Revenue by Application (2021-2032)
  7. 8.2.2 North America Bevacizumab Sales by Application (2021-2032)
  8. 8.2.3 North America Bevacizumab Price by Application (2021-2032)
  9. 8.3 North America Bevacizumab Market Size by Country
  10. 8.3.1 North America Bevacizumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Bevacizumab Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Bevacizumab Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Bevacizumab Market Size by Type
  2. 9.1.1 Europe Bevacizumab Revenue by Type (2021-2032)
  3. 9.1.2 Europe Bevacizumab Sales by Type (2021-2032)
  4. 9.1.3 Europe Bevacizumab Price by Type (2021-2032)
  5. 9.2 Europe Bevacizumab Market Size by Application
  6. 9.2.1 Europe Bevacizumab Revenue by Application (2021-2032)
  7. 9.2.2 Europe Bevacizumab Sales by Application (2021-2032)
  8. 9.2.3 Europe Bevacizumab Price by Application (2021-2032)
  9. 9.3 Europe Bevacizumab Market Size by Country
  10. 9.3.1 Europe Bevacizumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Bevacizumab Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Bevacizumab Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Bevacizumab Market Size by Type
  2. 10.1.1 China Bevacizumab Revenue by Type (2021-2032)
  3. 10.1.2 China Bevacizumab Sales by Type (2021-2032)
  4. 10.1.3 China Bevacizumab Price by Type (2021-2032)
  5. 10.2 China Bevacizumab Market Size by Application
  6. 10.2.1 China Bevacizumab Revenue by Application (2021-2032)
  7. 10.2.2 China Bevacizumab Sales by Application (2021-2032)
  8. 10.2.3 China Bevacizumab Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Bevacizumab Market Size by Type
  2. 11.1.1 Asia Bevacizumab Revenue by Type (2021-2032)
  3. 11.1.2 Asia Bevacizumab Sales by Type (2021-2032)
  4. 11.1.3 Asia Bevacizumab Price by Type (2021-2032)
  5. 11.2 Asia Bevacizumab Market Size by Application
  6. 11.2.1 Asia Bevacizumab Revenue by Application (2021-2032)
  7. 11.2.2 Asia Bevacizumab Sales by Application (2021-2032)
  8. 11.2.3 Asia Bevacizumab Price by Application (2021-2032)
  9. 11.3 Asia Bevacizumab Market Size by Country
  10. 11.3.1 Asia Bevacizumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Bevacizumab Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Bevacizumab Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Bevacizumab Market Size by Type
  2. 12.1.1 SAMEA Bevacizumab Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Bevacizumab Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Bevacizumab Price by Type (2021-2032)
  5. 12.2 SAMEA Bevacizumab Market Size by Application
  6. 12.2.1 SAMEA Bevacizumab Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Bevacizumab Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Bevacizumab Price by Application (2021-2032)
  9. 12.3 SAMEA Bevacizumab Market Size by Country
  10. 12.3.1 SAMEA Bevacizumab Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Bevacizumab Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Bevacizumab Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Bevacizumab Value Chain Analysis
  2. 13.1.1 Bevacizumab Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Bevacizumab Production Mode & Process
  6. 13.2 Bevacizumab Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Bevacizumab Distributors
  9. 13.2.3 Bevacizumab Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst